3-deazaguanine, a candidate drug for the chemotherapy of breast carcinomas?

Abstract

3-Deazaguanine (3-DG) is a new purine antagonist that is active against slow- and rapid-growing solid experimental tumors, especially those that are models for human breast carcinomas. These tumors include mammary adenocarcinomas 13762, R3230AC, and C3H/16C. 3-DG also showed positive activity against leukemias L1210 and L1210/araC, adenocarcinoma 755, and EMT-6 mammary adenocarcinoma. On the basis of its activity against these tumors, 3-DG is to undergo clinical trials.

• Authors: T A Khwaja
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 66 Issue 10 Pg. 1853-8 (Oct 1982) ISSN: 0361-5960 [Print] United States
• PMID: 7127323 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antimetabolites
• Guanine
• 3-deazaguanine

Topics

• Adenocarcinoma (drug therapy)
• Animals
• Antimetabolites (therapeutic use)
• Breast Neoplasms (drug therapy)
• Cell Line
• Female
• Guanine (analogs & derivatives, therapeutic use)
• Leukemia, Experimental (drug therapy)
• Mice
• Neoplasm Transplantation
• Rats